Subscribe
The FDA granted an accelerated approval to pembrolizumab plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
FDA Approves Frontline Nivolumab for Gastric Cancers
Nivolumab/Chemo Granted Priority Review for Frontline Metastatic Gastric, GEJ, and Esophageal Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2+ Gastric Adenocarcinomas
Margetuximab Granted Orphan Drug Status for Gastric Cancer
Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD
Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD
Kamel Abou Hussein, MD; Yelda Nouri, MD
Aditya Bardia, MD, MPH, FASCO; Benjamin Scheier, MD
Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO
Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO
September 12, 2026
Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS
Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD
Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA
Kamel Abou Hussein, MD; Kate Baxstrom, MD
Geoffrey Ku, MD; Jack W. Erter III, MD, MMHC
Ajit K. Bisen, MD, MBA; Virginia Kaklamani, MD, DSc